Enhancing tumor response to immunotherapy using chemokine modulation
Targeting the Chemokine System to Sensitize Tumors to Immunotherapy
This study is looking at new ways to help cancer treatments work better by helping immune cells get into tumors, especially for patients with melanoma, colorectal cancer, and ovarian cancer who haven't had success with current therapies.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-10916163 on NIH RePORTER |
What this research studies
This research investigates innovative methods to improve the effectiveness of immunotherapy for cancer patients by targeting the chemokine system. It focuses on enhancing the entry of immune cells into tumors, particularly in cases where tumors are resistant to current treatments. The approach involves using specific agents to increase the number of cytotoxic T lymphocytes (CTLs) while decreasing regulatory T cells in the tumor microenvironment. The research will evaluate the effectiveness of these strategies in patients with melanoma, colorectal cancer, and ovarian cancer, aiming to improve treatment outcomes for those who have not responded to existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with melanoma, colorectal cancer, or ovarian cancer who have not responded to PD-1 blockade therapies.
Not a fit: Patients with cancers that are not melanoma, colorectal, or ovarian, or those who have not undergone prior immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the effectiveness of immunotherapy for patients with difficult-to-treat cancers.
How similar studies have performed: Previous research has shown promising results in enhancing tumor response to immunotherapy using similar chemokine modulation strategies.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Kalinski, Pawel — Roswell Park Cancer Institute Corp
- Study coordinator: Kalinski, Pawel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.